Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 0.74 |
| ▸ | NPC1 | O15118 | 6/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8740257 | 0.88 | MEN1 (0.78) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL14054287 | 0.88 | RAB9A (0.84) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL14059092 | 0.87 | RAB9A (0.78) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL8741770 | 0.86 | MEN1 (0.76) | MEN1KMT2APOLBRAB9ANPC1 | |
| Bromide SCHEMBL14054264 | 0.86 | RAB9A (0.76) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL14053326 | 0.85 | RAB9A (1.00) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL8521727 | 0.84 | MEN1 (0.73) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL8740217 | 0.84 | MEN1 (0.73) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL6118406 | 0.83 | MEN1 (0.71) | MEN1KMT2APOLBRAB9ANPC1 | |
| SCHEMBL207431 | 0.83 | RAB9A (0.72) | MEN1KMT2APOLBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302573-A1 | METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302573-A1 | METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302573-A1 | METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090156611-A1 | MAMMALIAN HEDGEHOG SIGNALING MODULATORS | LICENTIA LTD. (FI) | 2009-06-18 | — | — | US | disclosed |
| US-20090156611-A1 | MAMMALIAN HEDGEHOG SIGNALING MODULATORS | LICENTIA LTD. (FI) | 2009-06-18 | — | — | US | disclosed |
| US-20070269420-A1 | Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases | VIROPHARMA INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070269420-A1 | Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases | VIROPHARMA INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| WO-2007054623-A2 | MAMMALIAN HEDGEHOG SIGNALING INHIABITORS | LICENTIA OY (FI) | 2007-05-18 | — | — | WO | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302573-A1 | METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION | MMP13, MMP8, MMP11 | MEN1 2970/4885KMT2A 4146/4885POLB 826/4885 |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | MEN1 3862/4885KMT2A 3476/4885POLB 2513/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | MEN1 3862/4885KMT2A 3476/4885POLB 2513/4885 |
| US-20070269420-A1 | Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases | HAVCR2, FABP1, LIPC | MEN1 4701/4885KMT2A 2832/4885POLB 175/4885 |
| US-20090156611-A1 | MAMMALIAN HEDGEHOG SIGNALING MODULATORS | SMO, SHH, GLI1 | MEN1 3274/4885KMT2A 2989/4885POLB 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.